Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma
International Journal of Molecular Sciences · 17.08.2023 · 24 (16) · 12886
DOI: 10.3390/ijms241612886 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.08.2023. Verfasst von Anita Maász und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary. Hauptthemen laut MEDLINE: Everolimus, Rhabdomyoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical School of University of Pécs, “ÁOK-KA” Research Program.
Abstract (Originalsprache)
Tuberous sclerosis complex (TSC) is a multisystem disorder characterized by seizures, neuropsychiatric disorders, and tumors of the heart, brain, skin, lungs, and kidneys. We present a three-year follow-up of a patient with TSC-associated rhabdomyoma detected in utero. Genetic examination of the fetus and the parents revealed a de novo variant in the TSC2 gene (c.3037delG, p.Asp1013IlefsTer3). Oral everolimus was initiated in the pregnant mother to regress the fetal tumor, which was successful. To the best of our knowledge, there is very little information regarding the use of everolimus therapy during pregnancy. West-syndrome was diagnosed when the proband was four months old. The symptoms were well-manageable, however temporarily. Therapy-resistant focal seizures were frequent. The patient had good vitals and was under regular cardiological control, showed a balanced circulation, and did not require any medication. Subependymal giant cell astrocytoma (SEGA) identified by regular neuroimaging examinations remained unchanged, which may be a consequence of early intrauterine treatment. Early detection of the pathogenic TSC2 variant, followed by in utero administration of everolimus and early vigabatrin therapy, allowed the detection of a milder developmental delay of the proband. Our study emphasizes how early genetic testing and management of epilepsy are pivotal for proper neurodevelopmental impacts and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary.
- Bethesda Children's Hospital, H-1146 Budapest, Hungary.
- Department of Obstetrics and Gynaecology, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary.
- Department of Paediatrics, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary.
- Department of Medical Imaging, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary.
ORCID-Profile: Anita Maász, Judit Bene, Kinga Hadzsiev
Förderung
- Medical School of University of Pécs, “ÁOK-KA” Research Program
Zitieren
APA
Maász, A., Bodó, T., Till, Á., Molnár, G., Masszi, G., Labossa, G., Herbert, Z., Bene, J., & Hadzsiev, K. (2023). Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma. International Journal of Molecular Sciences, 24(16), 12886. https://doi.org/10.3390/ijms241612886
Vancouver
Maász A, Bodó T, Till Á, Molnár G, Masszi G, Labossa G, et al. Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma. International Journal of Molecular Sciences. 2023;24(16):12886. doi:10.3390/ijms241612886
BibTeX
@article{Masz2023,
author = {Maász, Anita and Bodó, Tímea and Till, Ágnes and Molnár, Gábor and Masszi, György and Labossa, Gusztáv and Herbert, Zsuzsanna and Bene, Judit and Hadzsiev, Kinga},
title = {Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {12886},
doi = {10.3390/ijms241612886}
}
EUVIMED